{"gene":"CD52","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1991,"finding":"CD52 (CAMPATH-1 antigen) is a GPI-anchored glycoprotein with a remarkably short mature peptide of only 12–18 amino acid residues and one N-linked oligosaccharide at Asn3; its peptide backbone was determined by N-terminal sequencing and cDNA cloning, confirming GPI anchorage via phosphatidylinositol-specific phospholipase C sensitivity.","method":"Protein purification, N-terminal sequencing, PCR-based cDNA cloning, phospholipase C treatment","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — biochemical reconstitution and sequencing with multiple orthogonal methods in single foundational paper","pmids":["1711975"],"is_preprint":false},{"year":1993,"finding":"The antigenic epitope of CD52 recognized by CAMPATH-1 antibodies resides in the C-terminal tripeptide plus the GPI anchor region; proximity of the epitope to the cell membrane (not N-linked sugar or first nine amino acids) accounts for its efficiency as a complement lysis target. Both native and deglycosylated antigen and the proteolytic fragment can be reincorporated into target cells to confer sensitivity to lysis.","method":"Deglycosylation, proteolytic fragmentation, antigen reincorporation into target cells, complement lysis assay","journal":"Molecular immunology","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution and systematic mutagenesis/fragmentation with functional lysis readout","pmids":["8366859"],"is_preprint":false},{"year":1993,"finding":"CD52 is expressed at high level in the epididymis and on mature (but not testicular) spermatozoa, acquired during epididymal transit; its expression on sperm may involve transfer from epididymal epithelial cells. In the presence of complement, CAMPATH-1 antibodies inhibit sperm motility, but seminal plasma blocks antibody binding and protects sperm.","method":"Immunohistochemistry, complement-mediated motility inhibition assay","journal":"Journal of reproductive immunology","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization and functional complement assay in single study","pmids":["7685389"],"is_preprint":false},{"year":1993,"finding":"HE5, the most abundant human epididymal principal cell mRNA, encodes the same peptide backbone as the lymphocyte differentiation antigen CDw52, originating from the same single-copy gene, demonstrating that CD52 expression in the immune and reproductive systems arises from a shared gene with highly tissue-specific expression.","method":"Differential cDNA library screening, Northern blot, in situ hybridization, sequencing","journal":"Molecular reproduction and development","confidence":"High","confidence_rationale":"Tier 1 — direct sequencing and in situ hybridization with functional annotation","pmids":["8418821"],"is_preprint":false},{"year":1995,"finding":"Cross-linking of CD52 on normal human T lymphocytes induces proliferation and lymphokine production in purified CD4+ and CD8+ T cells (in the presence of phorbol esters or cross-linking antibodies); the activation signal is inhibited by cyclosporin A, implicating calcineurin-dependent pathways. CD52 cross-linking augments anti-CD3-mediated proliferation when co-immobilized but does not synergize with anti-CD2 or anti-CD28.","method":"T cell proliferation assay, lymphokine production, cyclosporin A inhibition, antibody cross-linking","journal":"International immunology","confidence":"High","confidence_rationale":"Tier 2 — clean primary T-cell functional assays with multiple conditions and pharmacological inhibition","pmids":["7718516"],"is_preprint":false},{"year":1996,"finding":"CD52 is expressed on human eosinophils (surface and mRNA) but not neutrophils; cross-linking CD52 on eosinophils dose-dependently inhibits reactive oxygen species production stimulated by C5a, platelet-activating factor, and GM-CSF, and CD52 is anchored by GPI (sensitive to PI-PLC). Phorbol ester down-regulates eosinophil CD52.","method":"Flow cytometry, RT-PCR, Northern blot, PI-PLC treatment, ROS assay with chemiluminescence, antibody cross-linking","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods in primary cells with functional readout","pmids":["8977262"],"is_preprint":false},{"year":1998,"finding":"Cross-linking CD52 on B-cell (Wien 133) and Jurkat T-cell lines causes growth inhibition and apoptosis (independent of Fas/FasL pathway); surviving cells down-regulate CD52 and other GPI-anchored molecules (CD59, CD55) but not transmembrane proteins, due to a defect in GPI precursor synthesis. This phenotype is reversible in B cells but stable in T cells, analogous to PNH.","method":"Cell growth assay, FACS, in vitro antibody cross-linking, flow cytometry, clone selection, nude mouse xenograft","journal":"Immunology","confidence":"Medium","confidence_rationale":"Tier 2 — clean KO/selection phenotype with multiple readouts; single lab","pmids":["9824507"],"is_preprint":false},{"year":1999,"finding":"Seminal plasma / male genital tract CD52 differs structurally from lymphocyte CD52: its GPI anchor contains 2-inositol palmitoylation (rendering it phospholipase C-resistant) and a sn-1-alkyl-2-lyso-glycerol structure, while N-glycans are highly charged, terminally sialylated, complex-type with branched lactosamine repeats and peripheral fucose not found on lymphocyte CD52.","method":"Western blot, structural glycan analysis, GPI anchor structural characterization by mass spectrometry","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — detailed structural mass spectrometric analysis with male-specific modifications confirmed","pmids":["10514467"],"is_preprint":false},{"year":2000,"finding":"CD52-mediated T-cell signal transduction requires co-expression of both the TCR and CD45 phosphatase; CD52 cross-linking triggers tyrosine phosphorylation events similar to anti-CD3, but without PLC-γ1 activation or Ca2+ signals. FRET demonstrated CD52 homo-association and CD52–TCR association at the cell surface. A model is proposed where CD52 cross-linking traps TCR within membrane complexes, inducing signals through CD45-regulated Lck and Fyn.","method":"Protein tyrosine phosphorylation assay, Jurkat CD52 transfectants, CD45-deficient subclones, FRET imaging","journal":"International immunology","confidence":"High","confidence_rationale":"Tier 1–2 — genetic (transfection/subclones) combined with FRET and biochemical signaling assays","pmids":["10744652"],"is_preprint":false},{"year":2002,"finding":"Monocyte-derived dendritic cells express abundant CD52 and are depleted by alemtuzumab, whereas Langerhans cells and dermal-interstitial DCs never express CD52 under steady-state or inflammatory conditions; monocyte-derived DC development in vitro does not require CD52, and anti-CD52 does not impair DC–T cell adhesion or DC-stimulated T cell proliferation.","method":"Flow cytometry, immunohistochemistry of skin/gut, in vitro DC differentiation, mixed lymphocyte reaction","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods across two independent Blood papers (PMIDs 12393688 and 12176892)","pmids":["12393688","12176892"],"is_preprint":false},{"year":2009,"finding":"In a human CD52 transgenic mouse model, alemtuzumab-mediated lymphocyte depletion and cytokine induction were largely independent of complement but dependent on neutrophils and NK cells, as demonstrated by depletion of these populations with anti-Gr-1 or anti-asialo-GM-1 antibodies, which strongly inhibited alemtuzumab activity, whereas cobra venom factor (complement removal) had no impact.","method":"Human CD52 transgenic mouse model, in vivo antibody depletion of neutrophils/NK cells, cobra venom factor complement depletion, serum cytokine assay, flow cytometry","journal":"Immunology","confidence":"High","confidence_rationale":"Tier 2 — epistasis in transgenic model with multiple depletion experiments and controls","pmids":["19740383"],"is_preprint":false},{"year":2009,"finding":"Neutrophils express CD52 mRNA and surface protein (at lower levels than lymphocytes/eosinophils), and incubation with alemtuzumab causes dose-dependent complement-mediated lysis of neutrophils, providing a mechanistic explanation for alemtuzumab-associated neutropenia.","method":"RT-PCR, flow cytometry with multiple anti-CD52 antibodies, complement lysis assay with autologous and heterologous complement","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 — direct lysis assay replicated with multiple antibodies; orthogonal mRNA and protein methods","pmids":["19638623"],"is_preprint":false},{"year":2013,"finding":"Human and mouse CD52hi CD4+ T cells suppress other T cells via soluble CD52 released by phospholipase C. Soluble CD52 binds the inhibitory receptor Siglec-10, impairing phosphorylation of TCR-associated kinases Lck and Zap70 and thereby suppressing T cell activation. This population is distinct from Foxp3+ Tregs.","method":"Co-immunoprecipitation, phosphokinase assay, phospholipase C cleavage, NOD mouse transfer model, flow cytometry, human type 1 diabetes cohort","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1–2 — mechanistic biochemistry (kinase phosphorylation), receptor identification (Co-IP), and in vivo transfer model","pmids":["23685786"],"is_preprint":false},{"year":2018,"finding":"Binding of soluble CD52 to Siglec-10 and T cell suppression requires the DAMP protein HMGB1: soluble CD52 binds specifically to the proinflammatory Box B domain of HMGB1, which in turn promotes binding of the CD52 N-linked glycan (in α-2,3 sialic acid linkage with galactose) to Siglec-10. This triggers Siglec-10 tyrosine phosphorylation, recruits SHP1 phosphatase to the Siglec-10 ITIM, and associates with the TCR, collectively suppressing T cell function. Anti-HMGB1 antibody or the Box A domain of HMGB1 blocks suppression.","method":"Co-immunoprecipitation, CD52-Fc binding assays, domain-specific HMGB1 competition, Siglec-10 phosphorylation assay, SHP1 recruitment assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — biochemical reconstitution with multiple interaction partners, mutagenesis-like domain competition, signaling readouts","pmids":["29997173"],"is_preprint":false},{"year":2017,"finding":"Soluble CD52 inhibits Toll-like receptor and TNF receptor signaling, limiting NF-κB activation and inflammatory cytokine production by macrophages, monocytes, and dendritic cells. At higher concentrations, soluble CD52 depletes MCL-1, activating BAX/BAK-dependent intrinsic apoptosis. In vivo, CD52 administration suppresses LPS-induced cytokine secretion and endotoxic shock, whereas CD52 genetic deletion exacerbates LPS responses.","method":"Soluble CD52 treatment of primary innate immune cells, NF-κB reporter assay, MCL-1/BAX/BAK western blot, CD52 knockout mouse LPS challenge model","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1–2 — KO mouse, in vitro pathway assays, and in vivo pharmacology with multiple orthogonal readouts","pmids":["29244050"],"is_preprint":false},{"year":2021,"finding":"Surface CD52 on B cells functions as an inhibitory regulator of BCR signaling: CD52-deficient JeKo-1 cells are hyperresponsive to BCR stimulation; antigen-specific BCR activation cleaves CD52 from the surface in a phospholipase C-dependent manner; soluble CD52-Fc inhibits BCR signaling partly via Siglec-10; and prolonged CD52 exposure expands IgD+IgMlo anergic B cells.","method":"CD52-deficient cell line, BCR signaling assay, phospholipase C inhibition, recombinant CD52-Fc treatment, single-cell RNA-seq, flow cytometry","journal":"Frontiers in immunology","confidence":"High","confidence_rationale":"Tier 1–2 — loss-of-function cell line with defined signaling phenotype, PI-PLC mechanism, Siglec-10 blocking, and anergy readout","pmids":["33658999"],"is_preprint":false},{"year":2021,"finding":"CD52 regulates monocyte adhesion and type I interferon signaling: CD52 overexpression decreases CD18 levels and monocyte adhesion, while CD52 knockdown increases adhesion. CD52 expression in monocytes is up-regulated by IL-4/IL-13 via STAT6 and down-regulated by LPS and type I/II IFNs via JAK1 and HDAC IIa.","method":"CD52 overexpression and knockdown in monocytes, monocyte adhesion assay, STAT6/JAK1/HDAC inhibitor experiments, flow cytometry, RNA-seq","journal":"Arthritis & rheumatology (Hoboken, N.J.)","confidence":"Medium","confidence_rationale":"Tier 2 — overexpression/knockdown with functional adhesion readout and pathway inhibition; single lab","pmids":["33760395"],"is_preprint":false},{"year":1998,"finding":"Crystal structures of rat anti-CD52 (CAMPATH-1G) Fab and its humanized counterpart (CAMPATH-1H) were solved at 2.6 Å and 3.25 Å, respectively. The antibody-combining site is dominated by protrusion of LysH52b and LysH53 from loop H2; framework residues H71 and H24 govern large conformational differences between rat and humanized loop H1, providing structural insight into antigen affinity and the basis for CDR grafting.","method":"X-ray crystallography","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 — crystal structures at defined resolution with functional interpretation","pmids":["9811544"],"is_preprint":false},{"year":2019,"finding":"A co-crystal structure of an anti-CD52 antibody Fab with a CD52 peptide mimetic (PDB 6OBD, 2.2 Å) revealed that Asn33 in light chain CDR1 directly contacts the CD52 phosphate group via a hydrogen bond, explaining the ~400-fold affinity loss upon Asn33 deamidation; Gly34 is away from the interface and mutagenesis at this site (G34R, G34K, G34Q) confers deamidation resistance while preserving binding and CDC activity.","method":"X-ray co-crystallography, surface plasmon resonance (Biacore), LC-MS peptide mapping, CDC assay, site-directed mutagenesis","journal":"mAbs","confidence":"High","confidence_rationale":"Tier 1 — crystal structure + mutagenesis + functional assay in one study","pmids":["31199181"],"is_preprint":false},{"year":2003,"finding":"In a murine ATL xenograft model, Campath-1H (alemtuzumab) anti-tumor killing in vivo requires FcR gamma-containing receptors (e.g., FcRγIII) on polymorphonuclear leukocytes and macrophages, mediating ADCC and/or cross-linking-induced apoptosis; FcRγ-knockout mice showed loss of Campath-1H efficacy.","method":"NOD/SCID xenograft model, FcRγ knockout mice, survival analysis","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with FcR knockout in vivo model","pmids":["14559836"],"is_preprint":false},{"year":1996,"finding":"CD52 expression in the rat epididymis is regulated by androgen level and temperature, and shows region-dependent poly(A) tail length differences: 'long' poly(A) tail CD52 mRNA in the cauda requires both androgens and testicular factors and is lost at abdominal temperature; 'short' poly(A) tail mRNA responds to androgens alone. This suggests posttranscriptional regulation of CD52 mRNA stability.","method":"Northern blot, castration/hormone replacement, efferent duct ligation, temperature manipulation in rats","journal":"Molecular reproduction and development","confidence":"Medium","confidence_rationale":"Tier 2 — genetic/hormonal manipulation with molecular readout; replicated in multiple conditions","pmids":["9364437"],"is_preprint":false},{"year":1996,"finding":"Body temperature (37°C) specifically and irreversibly suppresses CD52/CE5 mRNA levels in epididymal epithelial cell culture compared to 33°C, by a direct posttranscriptional mechanism affecting mRNA half-life, not mediated by testicular or androgenic factors and not affecting other epididymal mRNAs.","method":"Dog epididymal cell culture, temperature manipulation, mRNA stability assay with transcription/translation inhibitors","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — defined cell culture system with pharmacological dissection of mechanism","pmids":["8828507"],"is_preprint":false},{"year":2005,"finding":"Different CD52 glycoforms associate differently with membrane lipid microdomains: in leukocytes both the CAMPATH-epitope glycoform and the O-glycan-bearing glycoform are in cholesterol-rich lipid rafts, whereas in capacitated sperm the O-glycoform partitions into GM3-rich microdomains distinct from the cholesterol/GM1-rich rafts containing the CAMPATH-reactive glycoform. This differential raft association depends on glycan differences.","method":"Brij 98 detergent solubilization, sucrose gradient fractionation, heterologous CD52 insertion into rat sperm, Western blot","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — biochemical fractionation with cross-species insertion experiment; single lab","pmids":["16266689"],"is_preprint":false}],"current_model":"CD52 is a very short (12 amino acid mature peptide) GPI-anchored glycoprotein whose function depends critically on its N-linked glycan and GPI anchor: surface CD52 can transduce costimulatory signals in T cells by clustering with the TCR in a CD45- and Lck/Fyn-dependent manner, while soluble CD52 (released by phospholipase C upon activation) suppresses T and B cell function by sequestering HMGB1 Box B and presenting its α-2,3-sialylated N-glycan to the inhibitory receptor Siglec-10, triggering SHP1 recruitment to the Siglec-10 ITIM and impairing TCR/BCR kinase phosphorylation; additionally, soluble CD52 inhibits innate immune NF-κB signaling and can induce intrinsic apoptosis via MCL-1 depletion, while in the male reproductive tract a structurally distinct, inositol-palmitoylated GPI-anchored glycoform is progressively acquired by maturing spermatozoa during epididymal transit."},"narrative":{"teleology":[{"year":1991,"claim":"Establishing the molecular identity of CD52 resolved how such a small protein could serve as an abundant cell-surface antigen: it has only 12 mature residues, one N-glycan, and a GPI anchor.","evidence":"Protein purification, N-terminal sequencing, cDNA cloning, and PI-PLC sensitivity on lymphocytes","pmids":["1711975"],"confidence":"High","gaps":["Three-dimensional structure of the glycoprotein undetermined","Function of the single N-glycan unknown","Biological role of CD52 beyond serving as an antigen unresolved"]},{"year":1993,"claim":"Mapping the CAMPATH-1 epitope to the C-terminal tripeptide plus GPI anchor explained why the antibody is so efficient at triggering complement lysis—proximity to the membrane maximizes complement activation—and showed that the N-glycan and most of the peptide are dispensable for antibody recognition.","evidence":"Deglycosylation, proteolytic fragmentation, antigen reincorporation into target cells, complement lysis assay","pmids":["8366859"],"confidence":"High","gaps":["Atomic-level epitope structure not yet solved","How CD52 density on different cell types affects lysis efficiency unknown"]},{"year":1993,"claim":"Discovery that the most abundant epididymal transcript (HE5) encodes the same peptide as lymphocyte CD52 revealed a dual immune–reproductive biology for this gene, with CD52 acquired by spermatozoa during epididymal transit.","evidence":"Differential cDNA library screening, Northern blot, in situ hybridization, and sequence identity confirmation; immunohistochemistry and complement-mediated sperm motility inhibition","pmids":["8418821","7685389"],"confidence":"High","gaps":["Functional role of CD52 on sperm undefined","Mechanism of CD52 transfer from epididymal epithelium to sperm not characterized"]},{"year":1995,"claim":"Demonstrating that CD52 cross-linking induces cyclosporin A–sensitive T cell proliferation established that CD52 is not merely a passive surface marker but can actively costimulate T cells.","evidence":"Antibody cross-linking of CD52 on purified primary human CD4+ and CD8+ T cells, proliferation and lymphokine assays, cyclosporin A inhibition","pmids":["7718516"],"confidence":"High","gaps":["Proximal signaling intermediates unidentified","Relationship to TCR unclear","Whether costimulation occurs physiologically unknown"]},{"year":1996,"claim":"Detection of CD52 on eosinophils (but not neutrophils at the time) and its ability to inhibit ROS production upon cross-linking extended CD52 function beyond lymphocytes to innate effector cells with an inhibitory rather than costimulatory outcome.","evidence":"Flow cytometry, RT-PCR, Northern blot, PI-PLC treatment, chemiluminescence ROS assay on primary human eosinophils","pmids":["8977262"],"confidence":"High","gaps":["Mechanism of ROS inhibition downstream of GPI-anchored CD52 unknown","Relevance in eosinophilic disease not tested"]},{"year":1996,"claim":"Temperature- and androgen-dependent regulation of epididymal CD52 mRNA stability revealed posttranscriptional control mechanisms explaining why CD52 is expressed only in the scrotal environment.","evidence":"Northern blot with castration/hormone replacement in rats; dog epididymal cell culture temperature manipulation with transcription inhibitors","pmids":["9364437","8828507"],"confidence":"Medium","gaps":["RNA-binding factors mediating temperature-sensitive decay unidentified","Whether similar regulation occurs in human epididymis untested"]},{"year":1999,"claim":"Structural characterization of seminal CD52 glycoforms revealed inositol palmitoylation rendering the GPI anchor PLC-resistant and distinctive sialylated branched N-glycans, distinguishing reproductive from lymphocyte CD52 at the post-translational level.","evidence":"Mass spectrometry of GPI anchor and N-glycans from seminal plasma CD52","pmids":["10514467"],"confidence":"High","gaps":["Functional consequences of inositol palmitoylation on sperm unknown","Glycan-specific receptors on female reproductive tract undefined"]},{"year":2000,"claim":"Showing that CD52 costimulation requires co-expression of the TCR and CD45 phosphatase, triggers Lck/Fyn-dependent tyrosine phosphorylation without PLC-γ1 or Ca²⁺ signals, and that CD52 homo-associates and physically clusters with the TCR defined the proximal signaling mechanism of membrane-bound CD52.","evidence":"FRET imaging, protein tyrosine phosphorylation assays in Jurkat transfectants and CD45-deficient subclones","pmids":["10744652"],"confidence":"High","gaps":["Downstream transcription factor targets of CD52-TCR costimulation uncharacterized","Whether endogenous ligand for CD52 exists unknown"]},{"year":2003,"claim":"Demonstrating that alemtuzumab efficacy in vivo depends on FcγR-bearing effector cells (neutrophils, macrophages) rather than complement alone clarified the effector mechanism of therapeutic anti-CD52 antibody.","evidence":"NOD/SCID xenograft model with FcRγ-knockout mice and complement depletion; human CD52 transgenic mouse with neutrophil/NK depletion","pmids":["14559836","19740383"],"confidence":"High","gaps":["Relative contributions of ADCC vs. antibody-dependent phagocytosis not dissected","Whether FcγR dependence extends to all CD52-expressing cell types unknown"]},{"year":2013,"claim":"Identifying soluble CD52 as a suppressive mediator released by CD52hi T cells that engages the inhibitory receptor Siglec-10 to impair Lck/Zap70 phosphorylation established a new immunosuppressive axis distinct from Foxp3+ Tregs.","evidence":"Co-immunoprecipitation of CD52–Siglec-10, phosphokinase assays, PI-PLC cleavage, NOD mouse transfer model","pmids":["23685786"],"confidence":"High","gaps":["How selectivity for CD52hi cells is determined unknown","Whether soluble CD52 acts in trans on other immune cell types not tested","Structural basis of CD52–Siglec-10 interaction undefined"]},{"year":2017,"claim":"Extending soluble CD52 function to innate immunity showed it inhibits TLR/TNFR-driven NF-κB activation and, at higher concentrations, triggers MCL-1 depletion and BAX/BAK-dependent intrinsic apoptosis, with in vivo confirmation using CD52 knockout mice in endotoxic shock.","evidence":"NF-κB reporter assay, MCL-1/BAX/BAK western blot in macrophages/DCs, CD52 knockout mouse LPS challenge","pmids":["29244050"],"confidence":"High","gaps":["Direct molecular target upstream of NF-κB not identified","Whether MCL-1 depletion is Siglec-10-dependent or independent unknown"]},{"year":2018,"claim":"Demonstrating that HMGB1 Box B serves as a bridging cofactor between the α-2,3-sialylated N-glycan of soluble CD52 and Siglec-10 resolved how a small glycopeptide achieves receptor engagement, with HMGB1 sequestration additionally neutralizing its proinflammatory activity.","evidence":"Co-immunoprecipitation, CD52-Fc binding assays, domain-specific HMGB1 competition, Siglec-10 ITIM phosphorylation and SHP1 recruitment assays","pmids":["29997173"],"confidence":"High","gaps":["Stoichiometry of the ternary CD52–HMGB1–Siglec-10 complex undetermined","Structural model of the ternary complex lacking","Whether other DAMPs can substitute for HMGB1 unknown"]},{"year":2021,"claim":"Demonstrating that CD52 deletion renders B cells hyperresponsive to BCR stimulation and that BCR activation itself cleaves surface CD52 via PLC to generate soluble CD52 that feeds back through Siglec-10 unified the costimulatory and suppressive roles into a single activation-coupled negative feedback loop operating in B cells.","evidence":"CD52-deficient JeKo-1 cells, BCR signaling assays, PLC inhibition, recombinant CD52-Fc treatment, single-cell RNA-seq","pmids":["33658999"],"confidence":"High","gaps":["Whether the feedback loop operates equivalently in primary B cell subsets untested","Quantitative dynamics of CD52 shedding relative to BCR signal strength unknown"]},{"year":2021,"claim":"Showing that CD52 regulates monocyte adhesion by modulating CD18 surface levels and is itself transcriptionally controlled by STAT6 (IL-4/IL-13) and suppressed by IFN/JAK1/HDAC IIa linked CD52 to integrin-mediated monocyte functions and cytokine-directed gene regulation.","evidence":"CD52 overexpression/knockdown in monocytes, adhesion assay, STAT6/JAK1/HDAC inhibitor experiments, flow cytometry","pmids":["33760395"],"confidence":"Medium","gaps":["Mechanism by which CD52 reduces CD18 levels (direct vs. indirect) unknown","Relevance in autoimmune tissue infiltration not demonstrated in vivo"]},{"year":null,"claim":"Key unresolved questions include: whether an endogenous trans-ligand for membrane-bound CD52 exists, the three-dimensional structure of the CD52–HMGB1–Siglec-10 ternary complex, the functional role of CD52 on spermatozoa in fertilization, and whether CD52-mediated NF-κB suppression proceeds through Siglec-10 or an independent receptor.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model of CD52 glycoprotein or its ternary signaling complex","Sperm CD52 function in fertilization completely undefined","Innate immune receptor for soluble CD52 on macrophages not conclusively identified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[12,13,14,15]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[12,13]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1,5,8]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[12,13,14,15]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[12,13,14,15,16]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[6,14]}],"complexes":[],"partners":["SIGLEC10","HMGB1","PTPRC","LCK","FYN","PTPN6"],"other_free_text":[]},"mechanistic_narrative":"CD52 is a GPI-anchored glycoprotein with an exceptionally short mature peptide (12 amino acids) and a single N-linked glycan that functions as a bidirectional immune regulator: membrane-bound CD52 delivers costimulatory signals in T cells by clustering with the TCR in a CD45- and Lck/Fyn-dependent manner, while soluble CD52, released by phospholipase C cleavage upon lymphocyte activation, suppresses T cell, B cell, and innate immune responses by engaging the inhibitory receptor Siglec-10 through an HMGB1 Box B–dependent mechanism that recruits the SHP1 phosphatase to the Siglec-10 ITIM and impairs TCR/BCR kinase phosphorylation [PMID:10744652, PMID:23685786, PMID:29997173, PMID:33658999]. At higher concentrations soluble CD52 also inhibits NF-κB signaling downstream of TLR and TNF receptors and can trigger BAX/BAK-dependent intrinsic apoptosis via MCL-1 depletion [PMID:29244050]. Beyond the immune system, CD52 is the most abundant transcript in human epididymal principal cells and is progressively transferred to maturing spermatozoa during epididymal transit as a structurally distinct glycoform bearing inositol-palmitoylated GPI anchor and terminally sialylated complex N-glycans [PMID:8418821, PMID:10514467]."},"prefetch_data":{"uniprot":{"accession":"P31358","full_name":"CAMPATH-1 antigen","aliases":["CDw52","Cambridge pathology 1 antigen","Epididymal secretory protein E5","Human epididymis-specific protein 5","He5"],"length_aa":61,"mass_kda":6.6,"function":"May play a role in carrying and orienting carbohydrate, as well as having a more specific role","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P31358/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CD52","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1090,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CD52","total_profiled":1310},"omim":[{"mim_id":"114280","title":"CAMPATH-1 ANTIGEN; CD52","url":"https://www.omim.org/entry/114280"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"epididymis","ntpm":34113.9}],"url":"https://www.proteinatlas.org/search/CD52"},"hgnc":{"alias_symbol":["HE5","EDDM5"],"prev_symbol":["CDW52"]},"alphafold":{"accession":"P31358","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P31358","model_url":"https://alphafold.ebi.ac.uk/files/AF-P31358-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P31358-F1-predicted_aligned_error_v6.png","plddt_mean":67.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CD52","jax_strain_url":"https://www.jax.org/strain/search?query=CD52"},"sequence":{"accession":"P31358","fasta_url":"https://rest.uniprot.org/uniprotkb/P31358.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P31358/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P31358"}},"corpus_meta":[{"pmid":"9193354","id":"PMC_9193354","title":"Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.","date":"1997","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/9193354","citation_count":416,"is_preprint":false},{"pmid":"12130484","id":"PMC_12130484","title":"Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12130484","citation_count":386,"is_preprint":false},{"pmid":"12865797","id":"PMC_12865797","title":"Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).","date":"2003","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/12865797","citation_count":329,"is_preprint":false},{"pmid":"12543862","id":"PMC_12543862","title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12543862","citation_count":279,"is_preprint":false},{"pmid":"19740383","id":"PMC_19740383","title":"Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.","date":"2009","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19740383","citation_count":262,"is_preprint":false},{"pmid":"15070664","id":"PMC_15070664","title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15070664","citation_count":231,"is_preprint":false},{"pmid":"9593475","id":"PMC_9593475","title":"Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.","date":"1998","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/9593475","citation_count":219,"is_preprint":false},{"pmid":"23685786","id":"PMC_23685786","title":"T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10.","date":"2013","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23685786","citation_count":162,"is_preprint":false},{"pmid":"9215839","id":"PMC_9215839","title":"Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.","date":"1997","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/9215839","citation_count":161,"is_preprint":false},{"pmid":"9845524","id":"PMC_9845524","title":"Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9845524","citation_count":156,"is_preprint":false},{"pmid":"1711975","id":"PMC_1711975","title":"Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone.","date":"1991","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1711975","citation_count":153,"is_preprint":false},{"pmid":"24198283","id":"PMC_24198283","title":"Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24198283","citation_count":137,"is_preprint":false},{"pmid":"10918407","id":"PMC_10918407","title":"CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.","date":"2000","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/10918407","citation_count":136,"is_preprint":false},{"pmid":"17145843","id":"PMC_17145843","title":"Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).","date":"2006","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/17145843","citation_count":115,"is_preprint":false},{"pmid":"12393688","id":"PMC_12393688","title":"Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12393688","citation_count":113,"is_preprint":false},{"pmid":"9824507","id":"PMC_9824507","title":"Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells.","date":"1998","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9824507","citation_count":111,"is_preprint":false},{"pmid":"12176892","id":"PMC_12176892","title":"Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12176892","citation_count":109,"is_preprint":false},{"pmid":"7685389","id":"PMC_7685389","title":"The glycosylphosphatidylinositol-anchored lymphocyte antigen CDw52 is associated with the epididymal maturation of human spermatozoa.","date":"1993","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7685389","citation_count":98,"is_preprint":false},{"pmid":"14749699","id":"PMC_14749699","title":"Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia.","date":"2004","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/14749699","citation_count":98,"is_preprint":false},{"pmid":"8366859","id":"PMC_8366859","title":"Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen.","date":"1993","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8366859","citation_count":94,"is_preprint":false},{"pmid":"10514467","id":"PMC_10514467","title":"Male-specific modification of human CD52.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10514467","citation_count":90,"is_preprint":false},{"pmid":"28283679","id":"PMC_28283679","title":"The immunological function of CD52 and its targeting in organ transplantation.","date":"2017","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/28283679","citation_count":88,"is_preprint":false},{"pmid":"12949252","id":"PMC_12949252","title":"Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.","date":"2003","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12949252","citation_count":87,"is_preprint":false},{"pmid":"14559836","id":"PMC_14559836","title":"Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/14559836","citation_count":83,"is_preprint":false},{"pmid":"8418821","id":"PMC_8418821","title":"A major mRNA of the human epididymal principal cells, HE5, encodes the leucocyte differentiation CDw52 antigen peptide backbone.","date":"1993","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/8418821","citation_count":82,"is_preprint":false},{"pmid":"8977262","id":"PMC_8977262","title":"Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils.","date":"1996","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/8977262","citation_count":80,"is_preprint":false},{"pmid":"7632956","id":"PMC_7632956","title":"Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma.","date":"1995","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7632956","citation_count":80,"is_preprint":false},{"pmid":"7718516","id":"PMC_7718516","title":"Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes.","date":"1995","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7718516","citation_count":78,"is_preprint":false},{"pmid":"16688777","id":"PMC_16688777","title":"Activity of alemtuzumab in patients with CD52-positive acute leukemia.","date":"2006","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16688777","citation_count":72,"is_preprint":false},{"pmid":"29997173","id":"PMC_29997173","title":"CD52 glycan binds the proinflammatory B box of HMGB1 to engage the Siglec-10 receptor and suppress human T cell function.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29997173","citation_count":68,"is_preprint":false},{"pmid":"8027367","id":"PMC_8027367","title":"Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.","date":"1994","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/8027367","citation_count":66,"is_preprint":false},{"pmid":"19236377","id":"PMC_19236377","title":"Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.","date":"2009","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/19236377","citation_count":66,"is_preprint":false},{"pmid":"30144037","id":"PMC_30144037","title":"Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis.","date":"2018","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30144037","citation_count":62,"is_preprint":false},{"pmid":"9291477","id":"PMC_9291477","title":"Interaction of the human epididymal protein CD52 (HE5) with epididymal spermatozoa from men and cynomolgus monkeys.","date":"1997","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/9291477","citation_count":61,"is_preprint":false},{"pmid":"20348971","id":"PMC_20348971","title":"Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective.","date":"2010","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/20348971","citation_count":58,"is_preprint":false},{"pmid":"11257744","id":"PMC_11257744","title":"CD52 antigen--a review.","date":"2001","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/11257744","citation_count":56,"is_preprint":false},{"pmid":"29244050","id":"PMC_29244050","title":"CD52 inhibits Toll-like receptor activation of NF-κB and triggers apoptosis to suppress inflammation.","date":"2017","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/29244050","citation_count":53,"is_preprint":false},{"pmid":"11778765","id":"PMC_11778765","title":"Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.","date":"2001","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/11778765","citation_count":52,"is_preprint":false},{"pmid":"11114591","id":"PMC_11114591","title":"New insights into the origin, structure and role of CD52: a major component of the mammalian sperm glycocalyx.","date":"2001","source":"Cells, tissues, organs","url":"https://pubmed.ncbi.nlm.nih.gov/11114591","citation_count":52,"is_preprint":false},{"pmid":"14531909","id":"PMC_14531909","title":"Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H).","date":"2003","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/14531909","citation_count":51,"is_preprint":false},{"pmid":"21394097","id":"PMC_21394097","title":"CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression.","date":"2011","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/21394097","citation_count":48,"is_preprint":false},{"pmid":"17215854","id":"PMC_17215854","title":"Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody).","date":"2007","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/17215854","citation_count":48,"is_preprint":false},{"pmid":"19638623","id":"PMC_19638623","title":"Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19638623","citation_count":47,"is_preprint":false},{"pmid":"8828507","id":"PMC_8828507","title":"Body temperature (37 C) specifically down-regulates the messenger ribonucleic acid for the major sperm surface antigen CD52 in epididymal cell culture.","date":"1996","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/8828507","citation_count":47,"is_preprint":false},{"pmid":"17488672","id":"PMC_17488672","title":"Expression of CD52 in peripheral T-cell lymphoma.","date":"2007","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/17488672","citation_count":46,"is_preprint":false},{"pmid":"9373346","id":"PMC_9373346","title":"Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein.","date":"1995","source":"Immunotechnology : an international journal of immunological engineering","url":"https://pubmed.ncbi.nlm.nih.gov/9373346","citation_count":44,"is_preprint":false},{"pmid":"12714489","id":"PMC_12714489","title":"Expression of CD52 on plasma cells in plasma cell proliferative disorders.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12714489","citation_count":43,"is_preprint":false},{"pmid":"27925187","id":"PMC_27925187","title":"Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.","date":"2017","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27925187","citation_count":42,"is_preprint":false},{"pmid":"14632776","id":"PMC_14632776","title":"Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease.","date":"2003","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/14632776","citation_count":41,"is_preprint":false},{"pmid":"18086494","id":"PMC_18086494","title":"Long-term immune reconstitution after anti-CD52-treated or anti-CD34-treated hematopoietic stem cell transplantation for severe T-lymphocyte immunodeficiency.","date":"2007","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18086494","citation_count":40,"is_preprint":false},{"pmid":"6316259","id":"PMC_6316259","title":"Integration of viral DNA into the genome of the adenovirus type 2-transformed hamster cell line HE5 without loss or alteration of cellular nucleotides.","date":"1983","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/6316259","citation_count":38,"is_preprint":false},{"pmid":"9148769","id":"PMC_9148769","title":"Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism.","date":"1997","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/9148769","citation_count":37,"is_preprint":false},{"pmid":"26549384","id":"PMC_26549384","title":"Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies.","date":"2015","source":"Cytotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/26549384","citation_count":36,"is_preprint":false},{"pmid":"9659234","id":"PMC_9659234","title":"Activation of complement by human IgG1 and human IgG3 antibodies against the human leucocyte antigen CD52.","date":"1998","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9659234","citation_count":36,"is_preprint":false},{"pmid":"8671618","id":"PMC_8671618","title":"Emergence of CD52-, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment.","date":"1996","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8671618","citation_count":35,"is_preprint":false},{"pmid":"9464849","id":"PMC_9464849","title":"Human epididymal secreted protein CD52 on ejaculated spermatozoa: correlations with semen characteristics and the effect of its antibody.","date":"1997","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/9464849","citation_count":34,"is_preprint":false},{"pmid":"10744652","id":"PMC_10744652","title":"The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells.","date":"2000","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10744652","citation_count":34,"is_preprint":false},{"pmid":"9020367","id":"PMC_9020367","title":"Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52).","date":"1997","source":"European journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/9020367","citation_count":34,"is_preprint":false},{"pmid":"23123105","id":"PMC_23123105","title":"Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody.","date":"2012","source":"Clinical lymphoma, myeloma & leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/23123105","citation_count":34,"is_preprint":false},{"pmid":"14635201","id":"PMC_14635201","title":"CD52 expression in hairy cell leukemia.","date":"2003","source":"American journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/14635201","citation_count":33,"is_preprint":false},{"pmid":"19794084","id":"PMC_19794084","title":"Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia.","date":"2009","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/19794084","citation_count":33,"is_preprint":false},{"pmid":"11420384","id":"PMC_11420384","title":"Changes of the major sperm maturation-associated epididymal protein HE5 (CD52) on human ejaculated spermatozoa during incubation.","date":"2001","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/11420384","citation_count":30,"is_preprint":false},{"pmid":"1352921","id":"PMC_1352921","title":"The distribution of the CDW52 molecule on blood cells and characterization of its involvement in T cell activation.","date":"1992","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/1352921","citation_count":30,"is_preprint":false},{"pmid":"18067019","id":"PMC_18067019","title":"CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.","date":"2007","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/18067019","citation_count":29,"is_preprint":false},{"pmid":"8690449","id":"PMC_8690449","title":"Recognition of CD52 allelic gene products by CAMPATH-1H antibodies.","date":"1996","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8690449","citation_count":29,"is_preprint":false},{"pmid":"15390358","id":"PMC_15390358","title":"Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis.","date":"2005","source":"Pediatric blood & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15390358","citation_count":29,"is_preprint":false},{"pmid":"16019510","id":"PMC_16019510","title":"CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.","date":"2005","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/16019510","citation_count":28,"is_preprint":false},{"pmid":"24760752","id":"PMC_24760752","title":"CD52 is a molecular target in advanced systemic mastocytosis.","date":"2014","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/24760752","citation_count":28,"is_preprint":false},{"pmid":"33658999","id":"PMC_33658999","title":"CD52 Is Elevated on B cells of SLE Patients and Regulates B Cell Function.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33658999","citation_count":27,"is_preprint":false},{"pmid":"24799522","id":"PMC_24799522","title":"Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.","date":"2014","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/24799522","citation_count":27,"is_preprint":false},{"pmid":"9811544","id":"PMC_9811544","title":"Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart.","date":"1998","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9811544","citation_count":27,"is_preprint":false},{"pmid":"20848033","id":"PMC_20848033","title":"Expeditious chemoenzymatic synthesis of CD52 glycopeptide antigens.","date":"2010","source":"Organic & biomolecular chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20848033","citation_count":26,"is_preprint":false},{"pmid":"38242120","id":"PMC_38242120","title":"Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors.","date":"2024","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38242120","citation_count":25,"is_preprint":false},{"pmid":"14755312","id":"PMC_14755312","title":"Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics.","date":"2004","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/14755312","citation_count":25,"is_preprint":false},{"pmid":"16630656","id":"PMC_16630656","title":"Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells.","date":"2006","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/16630656","citation_count":25,"is_preprint":false},{"pmid":"15794865","id":"PMC_15794865","title":"CD52 expression in Waldenstrom's macroglobulinemia: implications for alemtuzumab therapy and response assessment.","date":"2005","source":"Clinical lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/15794865","citation_count":24,"is_preprint":false},{"pmid":"26372145","id":"PMC_26372145","title":"Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26372145","citation_count":24,"is_preprint":false},{"pmid":"17325855","id":"PMC_17325855","title":"CD52 expression in non-mycotic T- and NK/T-cell lymphomas.","date":"2007","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/17325855","citation_count":24,"is_preprint":false},{"pmid":"14662784","id":"PMC_14662784","title":"Vasectomy influences expression of HE1 but not HE2 and HE5 genes in human epididymis.","date":"2004","source":"Journal of andrology","url":"https://pubmed.ncbi.nlm.nih.gov/14662784","citation_count":23,"is_preprint":false},{"pmid":"23934027","id":"PMC_23934027","title":"Immune regulation by CD52-expressing CD4 T cells.","date":"2013","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23934027","citation_count":22,"is_preprint":false},{"pmid":"16266689","id":"PMC_16266689","title":"Different glycoforms of the human GPI-anchored antigen CD52 associate differently with lipid microdomains in leukocytes and sperm membranes.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16266689","citation_count":22,"is_preprint":false},{"pmid":"22336037","id":"PMC_22336037","title":"Porcine SWC1 is CD52--final determination by the use of a retroviral cDNA expression library.","date":"2012","source":"Veterinary immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/22336037","citation_count":22,"is_preprint":false},{"pmid":"10524207","id":"PMC_10524207","title":"Structure and chromosomal location of mouse and human CD52 genes.","date":"1999","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/10524207","citation_count":21,"is_preprint":false},{"pmid":"18223233","id":"PMC_18223233","title":"A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.","date":"2008","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/18223233","citation_count":21,"is_preprint":false},{"pmid":"16995884","id":"PMC_16995884","title":"Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia.","date":"2006","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/16995884","citation_count":21,"is_preprint":false},{"pmid":"11013436","id":"PMC_11013436","title":"Maturational changes of the CD52-like epididymal glycoprotein on cynomolgus monkey sperm and their apparent reversal in capacitation conditions.","date":"2000","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/11013436","citation_count":21,"is_preprint":false},{"pmid":"33760395","id":"PMC_33760395","title":"Regulation of Monocyte Adhesion and Type I Interferon Signaling by CD52 in Patients With Systemic Sclerosis.","date":"2021","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/33760395","citation_count":20,"is_preprint":false},{"pmid":"25087772","id":"PMC_25087772","title":"Anti-mouse CD52 monoclonal antibody ameliorates intestinal epithelial barrier function in interleukin-10 knockout mice with spontaneous chronic colitis.","date":"2015","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25087772","citation_count":20,"is_preprint":false},{"pmid":"28087077","id":"PMC_28087077","title":"Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment.","date":"2016","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/28087077","citation_count":20,"is_preprint":false},{"pmid":"11550272","id":"PMC_11550272","title":"Surface of human sperm bears three differently charged CD52 forms, two of which remain stably bound to sperm after capacitation.","date":"2001","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/11550272","citation_count":20,"is_preprint":false},{"pmid":"15720389","id":"PMC_15720389","title":"Kinetic and binding studies with purified recombinant proteins ferredoxin reductase, ferredoxin and cytochrome P450 comprising the morpholine mono-oxygenase from Mycobacterium sp. strain HE5.","date":"2005","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/15720389","citation_count":18,"is_preprint":false},{"pmid":"10737964","id":"PMC_10737964","title":"CD52 mRNA is modulated by androgens and temperature in epididymal cell cultures.","date":"2000","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/10737964","citation_count":18,"is_preprint":false},{"pmid":"9364437","id":"PMC_9364437","title":"Regionalized expression of CD52 in rat epididymis is related to mRNA poly(A) tail length.","date":"1997","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/9364437","citation_count":18,"is_preprint":false},{"pmid":"10050661","id":"PMC_10050661","title":"A sialoglycoprotein, gp20, of the human capacitated sperm surface is a homologue of the leukocyte CD52 antigen: analysis of the effect of anti-CD52 monoclonal antibody (CAMPATH-1) on capacitated spermatozoa.","date":"1999","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/10050661","citation_count":18,"is_preprint":false},{"pmid":"31199181","id":"PMC_31199181","title":"Engineering an anti-CD52 antibody for enhanced deamidation stability.","date":"2019","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/31199181","citation_count":17,"is_preprint":false},{"pmid":"35475910","id":"PMC_35475910","title":"Interleukin-15 augments NK cell-mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies.","date":"2023","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/35475910","citation_count":17,"is_preprint":false},{"pmid":"11549020","id":"PMC_11549020","title":"A cytochrome P450 and a ferredoxin isolated from Mycobacterium sp. strain HE5 after growth on morpholine.","date":"2001","source":"Applied microbiology and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/11549020","citation_count":17,"is_preprint":false},{"pmid":"28830605","id":"PMC_28830605","title":"Quantitative flow cytometric evaluation of CD200, CD123, CD43 and CD52 as a tool for the differential diagnosis of mature B-cell neoplasms.","date":"2017","source":"Revista brasileira de hematologia e hemoterapia","url":"https://pubmed.ncbi.nlm.nih.gov/28830605","citation_count":17,"is_preprint":false},{"pmid":"11986948","id":"PMC_11986948","title":"Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H.","date":"2002","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/11986948","citation_count":17,"is_preprint":false},{"pmid":"12021047","id":"PMC_12021047","title":"Analysis of a human sperm CD52 glycoform in primates: identification of an animal model for immunocontraceptive vaccine development.","date":"2002","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/12021047","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51041,"output_tokens":5810,"usd":0.120136},"stage2":{"model":"claude-opus-4-6","input_tokens":9418,"output_tokens":3637,"usd":0.207022},"total_usd":0.327158,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1991,\n      \"finding\": \"CD52 (CAMPATH-1 antigen) is a GPI-anchored glycoprotein with a remarkably short mature peptide of only 12–18 amino acid residues and one N-linked oligosaccharide at Asn3; its peptide backbone was determined by N-terminal sequencing and cDNA cloning, confirming GPI anchorage via phosphatidylinositol-specific phospholipase C sensitivity.\",\n      \"method\": \"Protein purification, N-terminal sequencing, PCR-based cDNA cloning, phospholipase C treatment\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical reconstitution and sequencing with multiple orthogonal methods in single foundational paper\",\n      \"pmids\": [\"1711975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The antigenic epitope of CD52 recognized by CAMPATH-1 antibodies resides in the C-terminal tripeptide plus the GPI anchor region; proximity of the epitope to the cell membrane (not N-linked sugar or first nine amino acids) accounts for its efficiency as a complement lysis target. Both native and deglycosylated antigen and the proteolytic fragment can be reincorporated into target cells to confer sensitivity to lysis.\",\n      \"method\": \"Deglycosylation, proteolytic fragmentation, antigen reincorporation into target cells, complement lysis assay\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution and systematic mutagenesis/fragmentation with functional lysis readout\",\n      \"pmids\": [\"8366859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"CD52 is expressed at high level in the epididymis and on mature (but not testicular) spermatozoa, acquired during epididymal transit; its expression on sperm may involve transfer from epididymal epithelial cells. In the presence of complement, CAMPATH-1 antibodies inhibit sperm motility, but seminal plasma blocks antibody binding and protects sperm.\",\n      \"method\": \"Immunohistochemistry, complement-mediated motility inhibition assay\",\n      \"journal\": \"Journal of reproductive immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization and functional complement assay in single study\",\n      \"pmids\": [\"7685389\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"HE5, the most abundant human epididymal principal cell mRNA, encodes the same peptide backbone as the lymphocyte differentiation antigen CDw52, originating from the same single-copy gene, demonstrating that CD52 expression in the immune and reproductive systems arises from a shared gene with highly tissue-specific expression.\",\n      \"method\": \"Differential cDNA library screening, Northern blot, in situ hybridization, sequencing\",\n      \"journal\": \"Molecular reproduction and development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct sequencing and in situ hybridization with functional annotation\",\n      \"pmids\": [\"8418821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Cross-linking of CD52 on normal human T lymphocytes induces proliferation and lymphokine production in purified CD4+ and CD8+ T cells (in the presence of phorbol esters or cross-linking antibodies); the activation signal is inhibited by cyclosporin A, implicating calcineurin-dependent pathways. CD52 cross-linking augments anti-CD3-mediated proliferation when co-immobilized but does not synergize with anti-CD2 or anti-CD28.\",\n      \"method\": \"T cell proliferation assay, lymphokine production, cyclosporin A inhibition, antibody cross-linking\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean primary T-cell functional assays with multiple conditions and pharmacological inhibition\",\n      \"pmids\": [\"7718516\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"CD52 is expressed on human eosinophils (surface and mRNA) but not neutrophils; cross-linking CD52 on eosinophils dose-dependently inhibits reactive oxygen species production stimulated by C5a, platelet-activating factor, and GM-CSF, and CD52 is anchored by GPI (sensitive to PI-PLC). Phorbol ester down-regulates eosinophil CD52.\",\n      \"method\": \"Flow cytometry, RT-PCR, Northern blot, PI-PLC treatment, ROS assay with chemiluminescence, antibody cross-linking\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods in primary cells with functional readout\",\n      \"pmids\": [\"8977262\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Cross-linking CD52 on B-cell (Wien 133) and Jurkat T-cell lines causes growth inhibition and apoptosis (independent of Fas/FasL pathway); surviving cells down-regulate CD52 and other GPI-anchored molecules (CD59, CD55) but not transmembrane proteins, due to a defect in GPI precursor synthesis. This phenotype is reversible in B cells but stable in T cells, analogous to PNH.\",\n      \"method\": \"Cell growth assay, FACS, in vitro antibody cross-linking, flow cytometry, clone selection, nude mouse xenograft\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KO/selection phenotype with multiple readouts; single lab\",\n      \"pmids\": [\"9824507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Seminal plasma / male genital tract CD52 differs structurally from lymphocyte CD52: its GPI anchor contains 2-inositol palmitoylation (rendering it phospholipase C-resistant) and a sn-1-alkyl-2-lyso-glycerol structure, while N-glycans are highly charged, terminally sialylated, complex-type with branched lactosamine repeats and peripheral fucose not found on lymphocyte CD52.\",\n      \"method\": \"Western blot, structural glycan analysis, GPI anchor structural characterization by mass spectrometry\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — detailed structural mass spectrometric analysis with male-specific modifications confirmed\",\n      \"pmids\": [\"10514467\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CD52-mediated T-cell signal transduction requires co-expression of both the TCR and CD45 phosphatase; CD52 cross-linking triggers tyrosine phosphorylation events similar to anti-CD3, but without PLC-γ1 activation or Ca2+ signals. FRET demonstrated CD52 homo-association and CD52–TCR association at the cell surface. A model is proposed where CD52 cross-linking traps TCR within membrane complexes, inducing signals through CD45-regulated Lck and Fyn.\",\n      \"method\": \"Protein tyrosine phosphorylation assay, Jurkat CD52 transfectants, CD45-deficient subclones, FRET imaging\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genetic (transfection/subclones) combined with FRET and biochemical signaling assays\",\n      \"pmids\": [\"10744652\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Monocyte-derived dendritic cells express abundant CD52 and are depleted by alemtuzumab, whereas Langerhans cells and dermal-interstitial DCs never express CD52 under steady-state or inflammatory conditions; monocyte-derived DC development in vitro does not require CD52, and anti-CD52 does not impair DC–T cell adhesion or DC-stimulated T cell proliferation.\",\n      \"method\": \"Flow cytometry, immunohistochemistry of skin/gut, in vitro DC differentiation, mixed lymphocyte reaction\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods across two independent Blood papers (PMIDs 12393688 and 12176892)\",\n      \"pmids\": [\"12393688\", \"12176892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In a human CD52 transgenic mouse model, alemtuzumab-mediated lymphocyte depletion and cytokine induction were largely independent of complement but dependent on neutrophils and NK cells, as demonstrated by depletion of these populations with anti-Gr-1 or anti-asialo-GM-1 antibodies, which strongly inhibited alemtuzumab activity, whereas cobra venom factor (complement removal) had no impact.\",\n      \"method\": \"Human CD52 transgenic mouse model, in vivo antibody depletion of neutrophils/NK cells, cobra venom factor complement depletion, serum cytokine assay, flow cytometry\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis in transgenic model with multiple depletion experiments and controls\",\n      \"pmids\": [\"19740383\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Neutrophils express CD52 mRNA and surface protein (at lower levels than lymphocytes/eosinophils), and incubation with alemtuzumab causes dose-dependent complement-mediated lysis of neutrophils, providing a mechanistic explanation for alemtuzumab-associated neutropenia.\",\n      \"method\": \"RT-PCR, flow cytometry with multiple anti-CD52 antibodies, complement lysis assay with autologous and heterologous complement\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct lysis assay replicated with multiple antibodies; orthogonal mRNA and protein methods\",\n      \"pmids\": [\"19638623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Human and mouse CD52hi CD4+ T cells suppress other T cells via soluble CD52 released by phospholipase C. Soluble CD52 binds the inhibitory receptor Siglec-10, impairing phosphorylation of TCR-associated kinases Lck and Zap70 and thereby suppressing T cell activation. This population is distinct from Foxp3+ Tregs.\",\n      \"method\": \"Co-immunoprecipitation, phosphokinase assay, phospholipase C cleavage, NOD mouse transfer model, flow cytometry, human type 1 diabetes cohort\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mechanistic biochemistry (kinase phosphorylation), receptor identification (Co-IP), and in vivo transfer model\",\n      \"pmids\": [\"23685786\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Binding of soluble CD52 to Siglec-10 and T cell suppression requires the DAMP protein HMGB1: soluble CD52 binds specifically to the proinflammatory Box B domain of HMGB1, which in turn promotes binding of the CD52 N-linked glycan (in α-2,3 sialic acid linkage with galactose) to Siglec-10. This triggers Siglec-10 tyrosine phosphorylation, recruits SHP1 phosphatase to the Siglec-10 ITIM, and associates with the TCR, collectively suppressing T cell function. Anti-HMGB1 antibody or the Box A domain of HMGB1 blocks suppression.\",\n      \"method\": \"Co-immunoprecipitation, CD52-Fc binding assays, domain-specific HMGB1 competition, Siglec-10 phosphorylation assay, SHP1 recruitment assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical reconstitution with multiple interaction partners, mutagenesis-like domain competition, signaling readouts\",\n      \"pmids\": [\"29997173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Soluble CD52 inhibits Toll-like receptor and TNF receptor signaling, limiting NF-κB activation and inflammatory cytokine production by macrophages, monocytes, and dendritic cells. At higher concentrations, soluble CD52 depletes MCL-1, activating BAX/BAK-dependent intrinsic apoptosis. In vivo, CD52 administration suppresses LPS-induced cytokine secretion and endotoxic shock, whereas CD52 genetic deletion exacerbates LPS responses.\",\n      \"method\": \"Soluble CD52 treatment of primary innate immune cells, NF-κB reporter assay, MCL-1/BAX/BAK western blot, CD52 knockout mouse LPS challenge model\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — KO mouse, in vitro pathway assays, and in vivo pharmacology with multiple orthogonal readouts\",\n      \"pmids\": [\"29244050\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Surface CD52 on B cells functions as an inhibitory regulator of BCR signaling: CD52-deficient JeKo-1 cells are hyperresponsive to BCR stimulation; antigen-specific BCR activation cleaves CD52 from the surface in a phospholipase C-dependent manner; soluble CD52-Fc inhibits BCR signaling partly via Siglec-10; and prolonged CD52 exposure expands IgD+IgMlo anergic B cells.\",\n      \"method\": \"CD52-deficient cell line, BCR signaling assay, phospholipase C inhibition, recombinant CD52-Fc treatment, single-cell RNA-seq, flow cytometry\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — loss-of-function cell line with defined signaling phenotype, PI-PLC mechanism, Siglec-10 blocking, and anergy readout\",\n      \"pmids\": [\"33658999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CD52 regulates monocyte adhesion and type I interferon signaling: CD52 overexpression decreases CD18 levels and monocyte adhesion, while CD52 knockdown increases adhesion. CD52 expression in monocytes is up-regulated by IL-4/IL-13 via STAT6 and down-regulated by LPS and type I/II IFNs via JAK1 and HDAC IIa.\",\n      \"method\": \"CD52 overexpression and knockdown in monocytes, monocyte adhesion assay, STAT6/JAK1/HDAC inhibitor experiments, flow cytometry, RNA-seq\",\n      \"journal\": \"Arthritis & rheumatology (Hoboken, N.J.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — overexpression/knockdown with functional adhesion readout and pathway inhibition; single lab\",\n      \"pmids\": [\"33760395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Crystal structures of rat anti-CD52 (CAMPATH-1G) Fab and its humanized counterpart (CAMPATH-1H) were solved at 2.6 Å and 3.25 Å, respectively. The antibody-combining site is dominated by protrusion of LysH52b and LysH53 from loop H2; framework residues H71 and H24 govern large conformational differences between rat and humanized loop H1, providing structural insight into antigen affinity and the basis for CDR grafting.\",\n      \"method\": \"X-ray crystallography\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures at defined resolution with functional interpretation\",\n      \"pmids\": [\"9811544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A co-crystal structure of an anti-CD52 antibody Fab with a CD52 peptide mimetic (PDB 6OBD, 2.2 Å) revealed that Asn33 in light chain CDR1 directly contacts the CD52 phosphate group via a hydrogen bond, explaining the ~400-fold affinity loss upon Asn33 deamidation; Gly34 is away from the interface and mutagenesis at this site (G34R, G34K, G34Q) confers deamidation resistance while preserving binding and CDC activity.\",\n      \"method\": \"X-ray co-crystallography, surface plasmon resonance (Biacore), LC-MS peptide mapping, CDC assay, site-directed mutagenesis\",\n      \"journal\": \"mAbs\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure + mutagenesis + functional assay in one study\",\n      \"pmids\": [\"31199181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"In a murine ATL xenograft model, Campath-1H (alemtuzumab) anti-tumor killing in vivo requires FcR gamma-containing receptors (e.g., FcRγIII) on polymorphonuclear leukocytes and macrophages, mediating ADCC and/or cross-linking-induced apoptosis; FcRγ-knockout mice showed loss of Campath-1H efficacy.\",\n      \"method\": \"NOD/SCID xenograft model, FcRγ knockout mice, survival analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with FcR knockout in vivo model\",\n      \"pmids\": [\"14559836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"CD52 expression in the rat epididymis is regulated by androgen level and temperature, and shows region-dependent poly(A) tail length differences: 'long' poly(A) tail CD52 mRNA in the cauda requires both androgens and testicular factors and is lost at abdominal temperature; 'short' poly(A) tail mRNA responds to androgens alone. This suggests posttranscriptional regulation of CD52 mRNA stability.\",\n      \"method\": \"Northern blot, castration/hormone replacement, efferent duct ligation, temperature manipulation in rats\",\n      \"journal\": \"Molecular reproduction and development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic/hormonal manipulation with molecular readout; replicated in multiple conditions\",\n      \"pmids\": [\"9364437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Body temperature (37°C) specifically and irreversibly suppresses CD52/CE5 mRNA levels in epididymal epithelial cell culture compared to 33°C, by a direct posttranscriptional mechanism affecting mRNA half-life, not mediated by testicular or androgenic factors and not affecting other epididymal mRNAs.\",\n      \"method\": \"Dog epididymal cell culture, temperature manipulation, mRNA stability assay with transcription/translation inhibitors\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined cell culture system with pharmacological dissection of mechanism\",\n      \"pmids\": [\"8828507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Different CD52 glycoforms associate differently with membrane lipid microdomains: in leukocytes both the CAMPATH-epitope glycoform and the O-glycan-bearing glycoform are in cholesterol-rich lipid rafts, whereas in capacitated sperm the O-glycoform partitions into GM3-rich microdomains distinct from the cholesterol/GM1-rich rafts containing the CAMPATH-reactive glycoform. This differential raft association depends on glycan differences.\",\n      \"method\": \"Brij 98 detergent solubilization, sucrose gradient fractionation, heterologous CD52 insertion into rat sperm, Western blot\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — biochemical fractionation with cross-species insertion experiment; single lab\",\n      \"pmids\": [\"16266689\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CD52 is a very short (12 amino acid mature peptide) GPI-anchored glycoprotein whose function depends critically on its N-linked glycan and GPI anchor: surface CD52 can transduce costimulatory signals in T cells by clustering with the TCR in a CD45- and Lck/Fyn-dependent manner, while soluble CD52 (released by phospholipase C upon activation) suppresses T and B cell function by sequestering HMGB1 Box B and presenting its α-2,3-sialylated N-glycan to the inhibitory receptor Siglec-10, triggering SHP1 recruitment to the Siglec-10 ITIM and impairing TCR/BCR kinase phosphorylation; additionally, soluble CD52 inhibits innate immune NF-κB signaling and can induce intrinsic apoptosis via MCL-1 depletion, while in the male reproductive tract a structurally distinct, inositol-palmitoylated GPI-anchored glycoform is progressively acquired by maturing spermatozoa during epididymal transit.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CD52 is a GPI-anchored glycoprotein with an exceptionally short mature peptide (12 amino acids) and a single N-linked glycan that functions as a bidirectional immune regulator: membrane-bound CD52 delivers costimulatory signals in T cells by clustering with the TCR in a CD45- and Lck/Fyn-dependent manner, while soluble CD52, released by phospholipase C cleavage upon lymphocyte activation, suppresses T cell, B cell, and innate immune responses by engaging the inhibitory receptor Siglec-10 through an HMGB1 Box B–dependent mechanism that recruits the SHP1 phosphatase to the Siglec-10 ITIM and impairs TCR/BCR kinase phosphorylation [PMID:10744652, PMID:23685786, PMID:29997173, PMID:33658999]. At higher concentrations soluble CD52 also inhibits NF-κB signaling downstream of TLR and TNF receptors and can trigger BAX/BAK-dependent intrinsic apoptosis via MCL-1 depletion [PMID:29244050]. Beyond the immune system, CD52 is the most abundant transcript in human epididymal principal cells and is progressively transferred to maturing spermatozoa during epididymal transit as a structurally distinct glycoform bearing inositol-palmitoylated GPI anchor and terminally sialylated complex N-glycans [PMID:8418821, PMID:10514467].\",\n  \"teleology\": [\n    {\n      \"year\": 1991,\n      \"claim\": \"Establishing the molecular identity of CD52 resolved how such a small protein could serve as an abundant cell-surface antigen: it has only 12 mature residues, one N-glycan, and a GPI anchor.\",\n      \"evidence\": \"Protein purification, N-terminal sequencing, cDNA cloning, and PI-PLC sensitivity on lymphocytes\",\n      \"pmids\": [\"1711975\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Three-dimensional structure of the glycoprotein undetermined\", \"Function of the single N-glycan unknown\", \"Biological role of CD52 beyond serving as an antigen unresolved\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Mapping the CAMPATH-1 epitope to the C-terminal tripeptide plus GPI anchor explained why the antibody is so efficient at triggering complement lysis—proximity to the membrane maximizes complement activation—and showed that the N-glycan and most of the peptide are dispensable for antibody recognition.\",\n      \"evidence\": \"Deglycosylation, proteolytic fragmentation, antigen reincorporation into target cells, complement lysis assay\",\n      \"pmids\": [\"8366859\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic-level epitope structure not yet solved\", \"How CD52 density on different cell types affects lysis efficiency unknown\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Discovery that the most abundant epididymal transcript (HE5) encodes the same peptide as lymphocyte CD52 revealed a dual immune–reproductive biology for this gene, with CD52 acquired by spermatozoa during epididymal transit.\",\n      \"evidence\": \"Differential cDNA library screening, Northern blot, in situ hybridization, and sequence identity confirmation; immunohistochemistry and complement-mediated sperm motility inhibition\",\n      \"pmids\": [\"8418821\", \"7685389\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional role of CD52 on sperm undefined\", \"Mechanism of CD52 transfer from epididymal epithelium to sperm not characterized\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Demonstrating that CD52 cross-linking induces cyclosporin A–sensitive T cell proliferation established that CD52 is not merely a passive surface marker but can actively costimulate T cells.\",\n      \"evidence\": \"Antibody cross-linking of CD52 on purified primary human CD4+ and CD8+ T cells, proliferation and lymphokine assays, cyclosporin A inhibition\",\n      \"pmids\": [\"7718516\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Proximal signaling intermediates unidentified\", \"Relationship to TCR unclear\", \"Whether costimulation occurs physiologically unknown\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Detection of CD52 on eosinophils (but not neutrophils at the time) and its ability to inhibit ROS production upon cross-linking extended CD52 function beyond lymphocytes to innate effector cells with an inhibitory rather than costimulatory outcome.\",\n      \"evidence\": \"Flow cytometry, RT-PCR, Northern blot, PI-PLC treatment, chemiluminescence ROS assay on primary human eosinophils\",\n      \"pmids\": [\"8977262\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of ROS inhibition downstream of GPI-anchored CD52 unknown\", \"Relevance in eosinophilic disease not tested\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Temperature- and androgen-dependent regulation of epididymal CD52 mRNA stability revealed posttranscriptional control mechanisms explaining why CD52 is expressed only in the scrotal environment.\",\n      \"evidence\": \"Northern blot with castration/hormone replacement in rats; dog epididymal cell culture temperature manipulation with transcription inhibitors\",\n      \"pmids\": [\"9364437\", \"8828507\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"RNA-binding factors mediating temperature-sensitive decay unidentified\", \"Whether similar regulation occurs in human epididymis untested\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Structural characterization of seminal CD52 glycoforms revealed inositol palmitoylation rendering the GPI anchor PLC-resistant and distinctive sialylated branched N-glycans, distinguishing reproductive from lymphocyte CD52 at the post-translational level.\",\n      \"evidence\": \"Mass spectrometry of GPI anchor and N-glycans from seminal plasma CD52\",\n      \"pmids\": [\"10514467\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequences of inositol palmitoylation on sperm unknown\", \"Glycan-specific receptors on female reproductive tract undefined\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Showing that CD52 costimulation requires co-expression of the TCR and CD45 phosphatase, triggers Lck/Fyn-dependent tyrosine phosphorylation without PLC-γ1 or Ca²⁺ signals, and that CD52 homo-associates and physically clusters with the TCR defined the proximal signaling mechanism of membrane-bound CD52.\",\n      \"evidence\": \"FRET imaging, protein tyrosine phosphorylation assays in Jurkat transfectants and CD45-deficient subclones\",\n      \"pmids\": [\"10744652\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream transcription factor targets of CD52-TCR costimulation uncharacterized\", \"Whether endogenous ligand for CD52 exists unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrating that alemtuzumab efficacy in vivo depends on FcγR-bearing effector cells (neutrophils, macrophages) rather than complement alone clarified the effector mechanism of therapeutic anti-CD52 antibody.\",\n      \"evidence\": \"NOD/SCID xenograft model with FcRγ-knockout mice and complement depletion; human CD52 transgenic mouse with neutrophil/NK depletion\",\n      \"pmids\": [\"14559836\", \"19740383\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of ADCC vs. antibody-dependent phagocytosis not dissected\", \"Whether FcγR dependence extends to all CD52-expressing cell types unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identifying soluble CD52 as a suppressive mediator released by CD52hi T cells that engages the inhibitory receptor Siglec-10 to impair Lck/Zap70 phosphorylation established a new immunosuppressive axis distinct from Foxp3+ Tregs.\",\n      \"evidence\": \"Co-immunoprecipitation of CD52–Siglec-10, phosphokinase assays, PI-PLC cleavage, NOD mouse transfer model\",\n      \"pmids\": [\"23685786\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How selectivity for CD52hi cells is determined unknown\", \"Whether soluble CD52 acts in trans on other immune cell types not tested\", \"Structural basis of CD52–Siglec-10 interaction undefined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Extending soluble CD52 function to innate immunity showed it inhibits TLR/TNFR-driven NF-κB activation and, at higher concentrations, triggers MCL-1 depletion and BAX/BAK-dependent intrinsic apoptosis, with in vivo confirmation using CD52 knockout mice in endotoxic shock.\",\n      \"evidence\": \"NF-κB reporter assay, MCL-1/BAX/BAK western blot in macrophages/DCs, CD52 knockout mouse LPS challenge\",\n      \"pmids\": [\"29244050\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular target upstream of NF-κB not identified\", \"Whether MCL-1 depletion is Siglec-10-dependent or independent unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrating that HMGB1 Box B serves as a bridging cofactor between the α-2,3-sialylated N-glycan of soluble CD52 and Siglec-10 resolved how a small glycopeptide achieves receptor engagement, with HMGB1 sequestration additionally neutralizing its proinflammatory activity.\",\n      \"evidence\": \"Co-immunoprecipitation, CD52-Fc binding assays, domain-specific HMGB1 competition, Siglec-10 ITIM phosphorylation and SHP1 recruitment assays\",\n      \"pmids\": [\"29997173\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of the ternary CD52–HMGB1–Siglec-10 complex undetermined\", \"Structural model of the ternary complex lacking\", \"Whether other DAMPs can substitute for HMGB1 unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrating that CD52 deletion renders B cells hyperresponsive to BCR stimulation and that BCR activation itself cleaves surface CD52 via PLC to generate soluble CD52 that feeds back through Siglec-10 unified the costimulatory and suppressive roles into a single activation-coupled negative feedback loop operating in B cells.\",\n      \"evidence\": \"CD52-deficient JeKo-1 cells, BCR signaling assays, PLC inhibition, recombinant CD52-Fc treatment, single-cell RNA-seq\",\n      \"pmids\": [\"33658999\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the feedback loop operates equivalently in primary B cell subsets untested\", \"Quantitative dynamics of CD52 shedding relative to BCR signal strength unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showing that CD52 regulates monocyte adhesion by modulating CD18 surface levels and is itself transcriptionally controlled by STAT6 (IL-4/IL-13) and suppressed by IFN/JAK1/HDAC IIa linked CD52 to integrin-mediated monocyte functions and cytokine-directed gene regulation.\",\n      \"evidence\": \"CD52 overexpression/knockdown in monocytes, adhesion assay, STAT6/JAK1/HDAC inhibitor experiments, flow cytometry\",\n      \"pmids\": [\"33760395\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which CD52 reduces CD18 levels (direct vs. indirect) unknown\", \"Relevance in autoimmune tissue infiltration not demonstrated in vivo\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: whether an endogenous trans-ligand for membrane-bound CD52 exists, the three-dimensional structure of the CD52–HMGB1–Siglec-10 ternary complex, the functional role of CD52 on spermatozoa in fertilization, and whether CD52-mediated NF-κB suppression proceeds through Siglec-10 or an independent receptor.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of CD52 glycoprotein or its ternary signaling complex\", \"Sperm CD52 function in fertilization completely undefined\", \"Innate immune receptor for soluble CD52 on macrophages not conclusively identified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [12, 13, 14, 15]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [12, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 5, 8]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [12, 13, 14, 15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [4, 8, 12, 13, 15]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [12, 13, 14, 15, 16]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [6, 14]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"SIGLEC10\",\n      \"HMGB1\",\n      \"PTPRC\",\n      \"LCK\",\n      \"FYN\",\n      \"PTPN6\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}